As filed with the U.S. Securities and Exchange Commission on February 4, 2021
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM S-1
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
BOLT BIOTHERAPEUTICS, INC.
(Exact Name of Registrant as Specified in its Charter)
| Delaware | 2834 | 47-2804636 | ||
(State or Other Jurisdiction of Incorporation or Organization) | (Primary Standard Industrial Classification Code Number) | (I.R.S. Employer Identification Number) |
Bolt Biotherapeutics, Inc.
900 Chesapeake Drive
Redwood City, California 94063
(650) 665-9295
(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive Offices)
Randall C. Schatzman, Ph.D.
Chief Executive Officer
Bolt Biotherapeutics, Inc.
900 Chesapeake Drive
Redwood City, California 94063
(650) 665-9295
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Copies to:
Sonya F. Erickson John T. McKenna Cooley LLP 1700 Seventh Avenue Seattle, Washington 98101 (206) 452-8753 | Alan F. Denenberg Stephen Salmon Davis Polk & Wardwell LLP 1600 El Camino Real Menlo Park, California 94025 (650) 752-2000 |
Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this registration statement.
If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box: ☐
If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☒ (File No. 333-252136)
If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer | ☐ | Accelerated filer | ☐ | |||
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ | |||
| Emerging growth company | ☒ | |||||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided to Section 7(a)(2)(B) of the Securities Act. ☒
CALCULATION OF REGISTRATION FEE
| ||||||||
Title of Each Class of Securities to be Registered | Amount to be Registered(1)(2) | Proposed Maximum Offering Price Per Share(3) | Proposed Maximum Aggregate Offering Price(3) | Amount of Registration Fee(4) | ||||
Common stock, par value $0.00001 per share | 1,150,000 | $20.00 | $23,000,000 | $2,510 | ||||
| ||||||||
| ||||||||
| (1) | Includes 150,000 shares that the underwriters have the option to purchase. |
| (2) | The Registrant is registering 1,150,000 shares pursuant to this Registration Statement, which shares are in addition to the 12,075,000 shares registered pursuant to the Registration Statement on Form S-1 (File No. 333-252136). |
| (3) | Estimated solely for the purpose of calculating the registration fee in accordance with Rule 457(a) of the Securities Act of 1933, as amended. |
| (4) | The registration fee is based upon the public offering price. |
This Registration Statement shall become effective upon filing in accordance with Rule 462(b) under the Securities Act of 1933, as amended.
EXPLANATORY NOTE AND INCORPORATION OF CERTAIN INFORMATION BY REFERENCE
Pursuant to Rule 462(b) under the Securities Act of 1933, as amended, Bolt Biotherapeutics, Inc. (the “Registrant”) is filing this Registration Statement on Form S-1 (this “Registration Statement”) with the Securities and Exchange Commission (the “Commission”). This Registration Statement relates to the public offering of securities contemplated by the Registration Statement on Form S-1, as amended (File No. 333-252136) (the “Prior Registration Statement”), which the Registrant originally filed with the Commission on January 15, 2021, and which the Commission declared effective on February 4, 2021.
The Registrant is filing this Registration Statement for the sole purpose of increasing the aggregate number of shares of common stock offered by the Registrant by 1,150,000 shares, 150,000 of which may be sold by the Registrant in the event the underwriters exercise their option to purchase additional shares of the Registrant’s common stock to cover over-allotments. The additional shares that are being registered for issuance and sale are in an amount and at a price that together represent no more than 20% of the maximum aggregate offering price set forth in the Calculation of Registration Fee table contained in the Prior Registration Statement. The information set forth in the Prior Registration Statement and all exhibits to the Prior Registration Statement are hereby incorporated by reference into this Registration Statement.
The required opinion and consents are listed on the Exhibit Index below and filed herewith.
EXHIBIT INDEX
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Redwood City, State of California, on February 4, 2021.
BOLT BIOTHERAPEUTICS, INC. | ||
By: | /s/ Randall C. Schatzman, Ph.D. | |
Name: | Randall C. Schatzman, Ph.D. | |
Title: | Chief Executive Officer | |
POWER OF ATTORNEY
Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.
| Signature | Title | Date | ||
/s/ Randall C. Schatzman, Ph.D. Randall C. Schatzman, Ph.D. | Chief Executive Officer and Director (Principal Executive Officer) | February 4, 2021 | ||
/s/ William P. Quinn William P. Quinn | Chief Financial Officer (Principal Financial and Accounting Officer) | February 4, 2021 | ||
* Peter Moldt, Ph.D. | Director | February 4, 2021 | ||
* Edgar G. Engleman, M.D. | Director | February 4, 2021 | ||
* James I. Healy, M.D. | Director | February 4, 2021 | ||
* Ashish Khanna, Ph.D. | Director | February 4, 2021 | ||
* Kathleen LaPorte | Director | February 4, 2021 | ||
* Richard A. Miller, M.D. | Director | February 4, 2021 | ||
* Mahendra G. Shah, Ph.D. | Director | February 4, 2021 | ||
*By: | /s/ Randall C. Schatzman, Ph.D. | |
| Randall C. Schatzman, Ph.D. | ||
| Attorney-in-Fact |
